NCT05440942View on ClinicalTrials.gov

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Trametinib

Trametinib will be administered orally once daily via tablet.

DRUG

Ruxolitinib

Ruxolitinib will be administered orally twice daily (BID) via tablet.

DRUG

Retifanlimab

Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..

Trial Locations (1)

33136

University of Miami, Miami

Sponsors
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

University of Miami Sylvester Comprehensive Cancer Center

OTHER

lead

Peter Hosein, MD

OTHER